WHO strongly advises against antibody treatments for COVID-19 patients

Written By :  Isra Zaman
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-09-20 04:00 GMT   |   Update On 2022-09-20 04:00 GMT
The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with covid-19, says a WHO Guideline Development Group of international experts in The BMJ today.
These drugs work by binding to the SARS-CoV-2 spike protein, neutralising the virus's ability to infect cells.
Today's strong recommendation replaces previous conditional recommendations for their use and is based on emerging evidence from laboratory studies that these drugs are not likely to work against currently circulating variants, such as omicron.
After weighing up all the evidence, the panel judged that almost all well informed patients would not choose to receive sotrovimab or casirivimab-imdevimab.
In the same guideline update, WHO makes a conditional recommendation for the use of the antiviral drug remdesivir in patients with severe covid-19, and a conditional recommendation against its use in patients with critical covid-19.
These recommendations are based on results from five randomised trials involving 7,643 patients, showing 13 fewer deaths per 1,000 patients with severe covid-19 taking remdesivir, but 34 more deaths per 1,000 patients with critical covid-19 taking the drug.
These new trial data provided sufficiently trustworthy evidence to demonstrate benefits in patients with severe covid-19, but not critical covid-19. The panel considered the benefits of remdesivir to be modest and of moderate certainty for key outcomes such as mortality and mechanical ventilation, resulting in a conditional recommendation.
WHO also advises that three drugs used to treat arthritis - the IL-6 receptor blockers tocilizumab or sarilumab and the JAK inhibitor baricitinib - may now be combined, in addition to corticosteroids, in patients with severe or critical covid-19.
However, the panel acknowledges some cost and resource implications associated with these drugs, which they say could exacerbate health inequities.
Reference:
Rapid Recommendations: A living WHO guideline on drugs for covid-19, The BMJ, DOI: 10.1136/bmj.m3379
Full View
Tags:    
Article Source : The BMJ

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News